 Selegiline
"Selegiline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
| Descriptor ID |
D012642
|
| MeSH Number(s) |
D02.092.471.683.915
|
| Concept/Terms |
Selegiline- Selegiline
- Selegiline, (R)-Isomer
- Selegyline
- L-Deprenyl
Emsam- Emsam
- Bristol-Myers Squibb Brand of Selegiline
- Bristol Myers Squibb Brand of Selegiline
Zelapar- Zelapar
- Valeant Brand of Selegiline
- Selegiline Valeant Brand
|
Below are MeSH descriptors whose meaning is more general than "Selegiline".
Below are MeSH descriptors whose meaning is more specific than "Selegiline".
This graph shows the total number of publications written about "Selegiline" by people in UAMS Profiles by year, and whether "Selegiline" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1990 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Selegiline" by people in Profiles over the past ten years.
-
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|